Physician profile
Ryan Abboud
NPI 1104353077
$2,684.00
in general payments reported to CMS, 2019-2025
19 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $295 · 2021: $1,084 · 2022: $724 · 2023: $312 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $821.63 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $447.63 | 2020-2023 | Repatha, Evenity, Prolia |
| Amarin Pharma, INC. | $398.30 | 2020-2022 | |
| Lilly USA, LLC | $188.66 | 2020-2023 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $155.17 | 2021-2022 | |
| Insmed, INC. | $144.88 | 2025 | Brinsupri |
| Biohaven Pharmaceutical Holding Company LTD. | $143.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.04 | 2020-2022 | |
| Dexcom, INC. | $52.26 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $31.60 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.44 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.43 | 2023 | Rexulti |
| Horizon Therapeutics Plc | $20.95 | 2021 | |
| Exact Sciences Corporation | $19.52 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $16.99 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.89 | 2022 | |
| Electromed, INC. | $15.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.97 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.